公开(公告)号：US20210290571A1

公开(公告)日：2021-09-23

申请号：US17257770

申请日：2019-07-12

Applicant: The Texas A&M University System

Inventor： Shivatheja Soma ,  Vishal M. Gohil ,  James C. Sacchettini ,  Liam Guthrie

IPC: A61K31/165 ,  A61K33/34 ,  A61P3/02

Abstract: In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTRL ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

公开(公告)号：US20240285555A1

公开(公告)日：2024-08-29

申请号：US18652683

申请日：2024-05-01

Applicant: The Texas A&M University System

Inventor： Shivatheja Soma ,  Vishal M. Gohil ,  James C. Sacchettini ,  Liam Guthrie

IPC: A61K31/165 ,  A61K33/34 ,  A61P3/02

CPC classification number: A61K31/165 ,  A61K33/34 ,  A61P3/02

Abstract: In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.